A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (metformin) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 6 week placebo single blind run in period followed by a 52-week a double blind treatment period and a 3-week follow-up period. Tesaglitazar and metformin will be titrated to optimal effect or highest tolerable dose during the first 12 weeks.
Inclusion Criteria:
Exclusion Criteria:
Carlisle, Arizona, United States
Sherwood, Arizona, United States
Carollton, Georgia, United States
Witchita, Kansas, United States
Kalamazoo, Missouri, United States
Pahrump, New York, United States
Rotenburg/Fulda, Germany
Bennebroe, Netherlands
San Vicente de Raspeig, Alicante, Spain
Berks, United Kingdom
Bucks, United Kingdom
Wiltshire, United Kingdom